Journal of Clinical & Experimental Pharmacology

Majumdar AS

Publications

• Research
  Therapeutic Promise of Dabigatran Etexilate, an Oral Direct Thrombin Inhibitor in a Preclinical Model of Colon Carcinogenesis
  Author(s): Sangole PN and Majumdar ASSangole PN and Majumdar AS
  
  Clinical observations suggest that there is activation of the coagulation system in patients of colon cancer. The resulting thrombin is implied in further exacerbation in the progression of colon cancer. We evaluated the effect of dabigatran etexilate (DE), an oral direct thrombin inhibitor in a preclinical model of 1, 2-Dimethylhydrazine (DMH) induced colon carcinogenesis in rats. DE reduced carcinogenesis induced gross morphological changes and colonic edema as compared to induced control. DE treatment significantly reduced levels of VEGF and ERK/MAPK and displayed a significant increase in colonic E-cadherin and reduction in N-cadherin, Twist and mTOR expression. Histopathologically, DE prevented the DMH induced adenocarcinomatous changes in the rat colon. Dual treatment of DE+5FU provided an additive effect as compared to the single treatment schedules of DE and 5FU, respectively... View More»
  DOI: 10.4172/2161-1459.1000247

  Abstract PDF